Biocept Inc. (BIOC)

2.25
0.09 3.85
NASDAQ : Health Technology
Prev Close 2.34
Open 2.38
Day Low/High 2.21 / 2.39
52 Wk Low/High 2.19 / 37.50
Volume 130.74K
Avg Volume 424.50K
Exchange NASDAQ
Shares Outstanding 2.27M
Market Cap 5.43M
EPS -23.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Announces Pricing Of $2.5 Million Registered Direct Offering Priced At Market

Biocept Announces Pricing Of $2.5 Million Registered Direct Offering Priced At Market

SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc.

Biocept Names Edwin C. Hendrick As Senior Vice President, Chief Commercial Officer

Biocept Names Edwin C. Hendrick As Senior Vice President, Chief Commercial Officer

SAN DIEGO, Sept. 10, 2018 /PRNewswire/ --  Biocept, Inc.

Biocept's Target Selector Platform Featured In Two Poster Presentations At The IASLC 19th World Conference On Lung Cancer

Biocept's Target Selector Platform Featured In Two Poster Presentations At The IASLC 19th World Conference On Lung Cancer

Clinical study data highlight the ability of Biocept's proprietary liquid biopsy technology to detect and monitor actionable biomarkers and circulating tumor cell counts in the blood and in cerebrospinal fluid of non-small cell lung cancer patients

Biocept Reports Second Quarter 2018 Financial Results

Biocept Reports Second Quarter 2018 Financial Results

Company to host conference call at 4:30 p.m. Eastern time today

Biocept To Release Second Quarter 2018 Financial Results And Host Investor Conference Call On August 14, 2018

Biocept To Release Second Quarter 2018 Financial Results And Host Investor Conference Call On August 14, 2018

SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc.

Biocept Announces $11.6 Million In Expected Gross Proceeds From Recently Expired Rights Offering

Biocept Announces $11.6 Million In Expected Gross Proceeds From Recently Expired Rights Offering

SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc.

Biocept Announces Agreement With Managed Care Plan To Study The Benefits Of Implementing Liquid Biopsy To Improve Patient Outcomes And Lower Healthcare Costs

Biocept Announces Agreement With Managed Care Plan To Study The Benefits Of Implementing Liquid Biopsy To Improve Patient Outcomes And Lower Healthcare Costs

Biocept's Target Selector™ to be used in profiling and monitoring patients diagnosed with non-small cell lung cancer throughout an integrated healthcare delivery system

Biocept Awarded Patent In Canada For Its Target Selector CTC Platform

Biocept Awarded Patent In Canada For Its Target Selector CTC Platform

Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs)

European Patent Granted For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Platform

European Patent Granted For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Platform

Expands intellectual property to 27 issued patents globally for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)

Biocept And UC San Diego Moores Cancer Center Announce Collaboration To Study Feasibility Of Liquid Biopsy To Predict Disease Recurrence In Solid Tumors And Response To Therapy

Biocept And UC San Diego Moores Cancer Center Announce Collaboration To Study Feasibility Of Liquid Biopsy To Predict Disease Recurrence In Solid Tumors And Response To Therapy

Clinical studies with Biocept's Target Selector™ to evaluate the use of circulating tumor cells in disease assessment, surveillance and monitoring

Biocept Reminds Investors Of Today's Deadline To Be A Shareholder Of Record

Biocept Reminds Investors Of Today's Deadline To Be A Shareholder Of Record

To be a shareholder of record, investors are advised to own Biocept stock by 4:00 PM ET, Thursday, July 19, 2018 to account for T+2 settlement timing

Biocept Enters Into Agreement With Alliance Global FZ To Market And Distribute Liquid Biopsy Testing In The Middle East, Southeast Asia, And Africa Region

Biocept Enters Into Agreement With Alliance Global FZ To Market And Distribute Liquid Biopsy Testing In The Middle East, Southeast Asia, And Africa Region

Expands international distribution of Target Selector™ platform to 17 countries

Biocept Informs Stockholders Of Key Dates And Terms Related To Announced Rights Offering

Biocept Informs Stockholders Of Key Dates And Terms Related To Announced Rights Offering

SAN DIEGO, July 11, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed...

Biocept Highlights Recent Progress And Outlines Near-Term Strategic Priorities In CEO Letter To Stockholders

Biocept Highlights Recent Progress And Outlines Near-Term Strategic Priorities In CEO Letter To Stockholders

SAN DIEGO, June 25, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer,...

Published Case Report Demonstrates The Clinical Utility Of Biocept's CTC Platform In The Management Of Patients With Metastatic Breast Cancer

Published Case Report Demonstrates The Clinical Utility Of Biocept's CTC Platform In The Management Of Patients With Metastatic Breast Cancer

Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept's Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive

VWR, Part Of Avantor, And Biocept Announce The Launch Of CEE-Sure Blood Collection Tubes For CfDNA And CTCs

VWR, Part Of Avantor, And Biocept Announce The Launch Of CEE-Sure Blood Collection Tubes For CfDNA And CTCs

Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature

Case Report In Journal Of Thoracic Oncology Demonstrates The Clinical Utility Of Biocept's Liquid Biopsy Test For Patient Diagnosed With Non-Small Cell Lung Cancer

Letter to the editor highlights capability of Target Selector™ test to detect ROS1, a lung cancer biomarker used to qualify patients for targeted therapies that can improve treatment outcomes

Published Case Study Demonstrates The Clinical Utility Of Biocept's Liquid Biopsy Test For ALK Rearrangements

Peer-reviewed article in Oncology & Hematology Review highlights capability of Target Selector™ to detect a key biomarker to qualify lung cancer patients for targeted therapy when tissue biopsy is inadequate

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) stock is surging in mid-morning trading on Tuesday after the company announced an agreement with Blue Cross Blue Shield of Illinois.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings...

Biocept To Present At 2015 Aegis Growth Conference

Biocept To Present At 2015 Aegis Growth Conference

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to...

TheStreet Quant Rating: E+ (Sell)